These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 917077)

  • 1. The FDA and the practice of medicine.
    Ryan KJ
    N Engl J Med; 1977 Dec; 297(23):1287-8. PubMed ID: 917077
    [No Abstract]   [Full Text] [Related]  

  • 2. FDA proposes more stringent pediatric-use labeling of prescription drug products.
    Clin Pharm; 1993 Jan; 12(1):6. PubMed ID: 8428434
    [No Abstract]   [Full Text] [Related]  

  • 3. FDA, off-label use, and informed consent: debunking myths and misconceptions.
    Beck JM; Azari ED
    Food Drug Law J; 1998; 53(1):71-104. PubMed ID: 11795338
    [No Abstract]   [Full Text] [Related]  

  • 4. Did FDA jump the gun?
    Archambault GF
    Hosp Formul; 1977 Oct; 12(10):722. PubMed ID: 10305387
    [No Abstract]   [Full Text] [Related]  

  • 5. Unapproved uses of approved drugs: The physician, the package insert, and the FDA.
    Pediatrics; 1978 Aug; 62(2):262-4. PubMed ID: 693165
    [No Abstract]   [Full Text] [Related]  

  • 6. FDA proposes more stringent pediatric-use labeling of prescription drug products.
    Am J Hosp Pharm; 1993 Jan; 50(1):13, 16. PubMed ID: 8427271
    [No Abstract]   [Full Text] [Related]  

  • 7. Regulating off-label drug use--rethinking the role of the FDA.
    Stafford RS
    N Engl J Med; 2008 Apr; 358(14):1427-9. PubMed ID: 18385495
    [No Abstract]   [Full Text] [Related]  

  • 8. From off-label prescribing towards a new FDA.
    Tabarrok A
    Med Hypotheses; 2009 Jan; 72(1):11-3. PubMed ID: 18835103
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Rx-to-OTC switch of Claritin, Allegra, and Zyrtec: an unprecedented FDA response to petitioners and the protection of public health.
    Spencer HM
    Am Univ Law Rev; 2002 Jun; 51(5):999-1050. PubMed ID: 12197546
    [No Abstract]   [Full Text] [Related]  

  • 10. FDA warns about fraudulent STD treatments.
    AIDS Patient Care STDS; 2008 Apr; 22(4):353. PubMed ID: 18434953
    [No Abstract]   [Full Text] [Related]  

  • 11. Prescription drug products; revocation of patient package insert requirements--Food and Drug Administration. Final rule.
    Fed Regist; 1982 Sep; 47(173):39147-55. PubMed ID: 10258154
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Requirements for submission of labeling for human prescription drugs and biologics in electronic format. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2003 Dec; 68(238):69009-20. PubMed ID: 14672084
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Off-label drugs: question your doctor.
    Consum Rep; 2007 Jun; 72(6):47. PubMed ID: 17632948
    [No Abstract]   [Full Text] [Related]  

  • 14. Off-label pharmaceutical use: balancing information, risks, and benefits.
    Kozma CM
    Manag Care Interface; 2004 Jan; 17(1):29-30. PubMed ID: 15035597
    [No Abstract]   [Full Text] [Related]  

  • 15. Drug promotion.
    Kalish RS
    N Engl J Med; 1995 Apr; 332(15):1032; author reply 1033. PubMed ID: 7794341
    [No Abstract]   [Full Text] [Related]  

  • 16. Institute of Medicine's new drug safety report: implications for Canada.
    Cassels A
    CMAJ; 2006 Dec; 175(12):1515-6. PubMed ID: 17146086
    [No Abstract]   [Full Text] [Related]  

  • 17. Positive outcomes through the appropriate use of off-label prescribing.
    Bright JL
    Arch Intern Med; 2006 Dec 11-25; 166(22):2554-5; author reply 2555. PubMed ID: 17159026
    [No Abstract]   [Full Text] [Related]  

  • 18. A voluntary disclosure program for FDA--the time has come.
    Fleder JR
    Food Drug Law J; 1999; 54(3):389-99. PubMed ID: 11797705
    [No Abstract]   [Full Text] [Related]  

  • 19. Pharmaceutical inserts: legal consequences.
    Hirsh HL
    Hosp Med Staff; 1979 Jul; 8(7):2-6. PubMed ID: 10242674
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Going off-label without venturing off-course: evidence and ethical off-label prescribing.
    Largent EA; Miller FG; Pearson SD
    Arch Intern Med; 2009 Oct; 169(19):1745-7. PubMed ID: 19858430
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.